Asymchen combines molecular biology technology
Asymchen combines molecular biology technology, fermentation technology and process development technology to provide customers with carbapenems, cGMP APIs and other products used in anti-viral, anti-cancer, cardiovascular and cerebrovascular diseases, diabetes and other major diseases, and cooperates with Novartis, Bristol-Myers Squibb, AstraZeneca and GlaxoSmithKline.
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchReal Estate, Industrials, Financials
Tech for Global, Globalization Footprints of the Established and the New
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM